Analogous to LDL-c, the lower the better also seems true for inflammation
AHA 2017 - Anaheim, CA, USANov. 14, 2017 - Paul Ridker, Boston, MA, USA
AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.
This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
Prof. Paul Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.
- Our reporting is based on the information provided at the AHA 2017 congress -